LONDON – Immune Targeting Systems Ltd. (ITS) presented positive data on its universal influenza vaccine, Flunisyn, showing that it induced T-cell responses in 95 percent of subjects in an elderly population, ages 65 to 74, in a Phase IIa trial.
Read More
A new study has connected known differences in the metabolism typical of cancer cells to the pathway leading to apoptosis, or cell death. Researchers working in Finland have, for the first time, linked metabolic changes in cancer cells to the mechanism that, in normal cells, prevents abnormal cellular proliferation. The discovery is likely to encourage drug developers to consider whether existing drugs that modify cellular metabolism could be used in the future to treat cancer.
Read More
DUBLIN, Ireland – Royalty Pharma upped the ante in its efforts to land Elan Corp. plc by raising its bid to $12 per share, an offer that values the Dublin, Ireland-based biotech at around $7.3 billion.
Read More
Santaris Pharma A/S is getting $10 million up front and could earn up to $90 million more in per-product milestones from a multiproduct drug discovery alliance with Bristol-Myers Squibb Co., based on its Locked Nucleic Acid (LNA) antisense technology. Read More
Photocure ASA claimed it has taken photodynamic therapy (PDT) "to a completely new level," as it published positive data from the final analysis of the 262-patient Phase IIb trial of Cervira in treating oncogenic human papillomavirus (HPV) infections and pre-cancerous lesions of the cervix.
Read More
Lipid Therapeutics GmbH aims to extend its pivotal program for its ulcerative colitis treatment LT-02 into the U.S., following an investigational new drug grant from the FDA that will enable it and its partner, Dr. Falk Pharma GmbH, to conduct a joint Phase III program on either side of the Atlantic. The plan depends on the company finding a U.S. partner, however.
Read More
• Innate Pharma SA, of Marseille, France, reported preclinical data for two of its programs. For its IPH33 program, it reported that humanized anti-TLR3 antibodies showed efficient blocking of TLR3 signaling with high potency.
Read More